Belgium-based Agomab Therapeutics NV has recruited two executives to lead its research programme and manage intellectual property as it advances its pipeline of treatments for fibrosis, tissue repair, and the restoration of organ function. Reginald Brys will direct research and Maria Nichol will oversee IP. Both individuals are joining Agomab from Galapagos NV. Dr Brys holds a PhD from Keu Leuven in Belgium. At Galapagos, he was head of disease biology. Dr Nichol has a DPhil in Alzheimer’s disease from the University of Oxford, UK and is a European patent attorney and chartered patent attorney.
Agomab announced the appointment on 21 December 2021.
Copyright 2022 Evernow Publishing Ltd